GCTK.NASDAQGlucotrack, INC

Form 4: Andrew Balo Acquires Shares in Glucotrack, Inc.

Sentiment:

SEC Form 4 Filing

📋All filings for Glucotrack, INC
🔒Login to Follow

Director Andrew Balo acquired 4,490 shares of Glucotrack, Inc. common stock on March 26, 2025.

Summary

  • On March 26, 2025, Andrew Balo, a director of Glucotrack, Inc., acquired 4,490 shares of common stock.
  • The acquisition was a direct transaction.
  • Following the transaction, Balo directly owns 4,490 shares of Glucotrack, Inc.
  • The filing reflects reverse stock splits implemented by Glucotrack, Inc. on May 17, 2024 (1-for-5) and February 25, 2025 (1-for-20).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a transaction by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders such as directors and officers trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

  • The transaction may have a minor impact on shareholder sentiment, as insider transactions are often viewed as a signal of confidence (or lack thereof) in the company's prospects.

Key Dates

DateDescription
May 17, 20241-for-5 reverse stock split of Glucotrack's common stock.
February 25, 20251-for-20 reverse stock split of Glucotrack's common stock.
March 26, 2025Andrew Balo acquired 4,490 shares of Glucotrack, Inc. common stock.
March 28, 2025Date of signature for the Form 4 filing.

Keywords

Glucotrack, Andrew Balo, stock acquisition, Form 4, director, GCTK, reverse stock split, beneficial ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.